SEDI Insider filing browser
Filter by Company
×
Filter by $CAD Amount
×
Filter by Filing Type
Filter by Insider
×
 
Date Issuer Insider Transaction Amount New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
Filed 2023-06-25 23:16
Tx date 2023-06-20
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Deferred Share Units (DSU)
56 - Grant of rights
$11,750
+18,077 vol
$0.65 each
51,710
Filed 2022-05-19 22:01
Tx date 2022-05-18
$MRV
Nuvo Pharmaceuticals Inc. (d/b/a Miravo Healthcare)
London, John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Deferred Share Unit Plan (DSU)
56 - Grant of rights

+12,113 vol
19,793
Filed 2022-05-17 12:57
Tx date 2022-05-13
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Deferred Share Units (DSU)
56 - Grant of rights

+16,096 vol
33,633
Filed 2022-04-03 21:21
Tx date 2022-03-29
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Options
52 - Expiration of options

-44,368 vol
117,658
Filed 2021-12-28 11:40
Tx date 2021-12-22
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Deferred Share Units (DSU)
56 - Grant of rights

+17,537 vol
17,537
Filed 2021-12-28 11:38
Tx date 2016-03-01
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Deferred Share Units (DSU)
00 - Opening Balance-Initial SEDI Report
Filed 2021-12-22 11:30
Tx date 2021-12-21
$MRV
Nuvo Pharmaceuticals Inc. (d/b/a Miravo Healthcare)
London, John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
38 - Redemption, retraction, cancellation, repurchase

-44,368 vol
275,103
Filed 2021-08-26 15:31
Tx date 2021-08-16
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Options
52 - Expiration of options
$-10,623.7472
-8,812 vol
$1.21 each
162,026
Filed 2021-08-17 08:35
Tx date 2021-08-17
$MRV
Nuvo Pharmaceuticals Inc. (d/b/a Miravo Healthcare)
London, John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
52 - Expiration of options

-8,812 vol
319,471
Filed 2021-05-21 12:14
Tx date 2021-05-20
$MRV
Nuvo Pharmaceuticals Inc. (d/b/a Miravo Healthcare)
London, John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Deferred Share Unit Plan (DSU)
56 - Grant of rights

+7,680 vol
7,680
Filed 2020-08-21 21:36
Tx date 2020-08-17
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
$6,000
+10,000 vol
$0.60 each
170,838
Filed 2020-06-17 15:52
Tx date 2020-06-17
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Options
52 - Expiration of options

-16,608 vol
160,838
Filed 2020-06-16 16:06
Tx date 2020-06-16
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.)
London, John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
52 - Expiration of options

-16,608 vol
328,283
Filed 2020-05-14 13:58
Tx date 2020-05-13
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.)
London, John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+7,000 vol
344,891
Filed 2019-08-19 15:30
Tx date 2019-08-19
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.)
London, John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+7,000 vol
337,891
Filed 2019-05-25 14:49
Tx date 2019-05-21
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
$7,800
+10,000 vol
$0.78 each
177,446
Filed 2019-05-24 12:09
Tx date 2019-05-21
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
$7,800
+10,000 vol
$0.78 each
Filed 2019-05-24 12:09
Tx date 2019-05-21
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
$7,800
+10,000 vol
$0.78 each
177,446
Filed 2019-01-08
Tx date 2019-01-04
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+10,000 vol
167,446
Filed 2019-01-03
Tx date 2019-01-03
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.)
London, John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Share Appreciation Rights Plan (SAR)
38 - Redemption, retraction, cancellation, repurchase

-17,195 vol
0
Filed 2019-01-03
Tx date 2019-01-03
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Share Appreciation Rights Plan (SAR)
38 - Redemption, retraction, cancellation, repurchase

-17,195 vol
0
Filed 2018-04-06
Tx date 2018-04-03
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+10,000 vol
157,446
Filed 2018-03-29
Tx date 2017-12-06
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.)
London, John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
52 - Expiration of options

-53,846 vol
Filed 2018-03-29
Tx date 2017-11-07
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.)
London, John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
52 - Expiration of options

-53,846 vol
323,891
Filed 2018-03-29
Tx date 2017-12-06
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Options
52 - Expiration of options

-53,846 vol
Filed 2018-03-29
Tx date 2017-11-07
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Options
52 - Expiration of options

-53,846 vol
147,446
Filed 2018-03-29
Tx date 2017-12-06
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Options
52 - Expiration of options

-53,846 vol
Filed 2018-03-28
Tx date 2018-03-28
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.)
London, John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+7,000 vol
330,891
Filed 2018-03-16
Tx date 2018-02-16
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Rights Crescita Rights Offering
56 - Grant of rights

+75,472 vol
75,472
Filed 2018-03-16
Tx date 2016-03-01
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Holder: TFSA (Indirect Ownership)
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2018-03-16
Tx date 2016-03-01
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Holder: Spousal TFSA (Control or Direction)
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2018-03-16
Tx date 2018-03-13
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Holder: Spousal TFSA (Control or Direction)
Common Shares
57 - Exercise of rights
$4,000
+7,548 vol
$0.53 each
7,548
Filed 2018-03-16
Tx date 2018-03-13
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Holder: TFSA (Indirect Ownership)
Common Shares
57 - Exercise of rights
$15,999
+30,188 vol
$0.53 each
30,188
Filed 2018-03-16
Tx date 2016-03-01
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Rights Crescita Rights Offering
00 - Opening Balance-Initial SEDI Report
Filed 2018-03-16
Tx date 2018-03-13
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Rights Crescita Rights Offering
57 - Exercise of rights
$-40,000.16
-75,472 vol
$0.53 each
0
Filed 2018-03-13
Tx date 2018-03-13
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.)
London, John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: RRSP (Indirect Ownership)
Common Shares
90 - Change in the nature of ownership

+473 vol
473
Filed 2018-03-13
Tx date 2018-03-13
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.)
London, John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
90 - Change in the nature of ownership

-473 vol
155,313
Filed 2018-03-13
Tx date 2004-09-21
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.)
London, John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: RRSP (Indirect Ownership)
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2018-01-03
Tx date 2018-01-01
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.)
London, John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Share Appreciation Rights Plan (SAR)
59 - Exercise for cash
$-82,080.80
-22,184 vol
$3.70 each
17,195
Filed 2018-01-03
Tx date 2018-01-01
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Share Appreciation Rights Plan (SAR)
38 - Redemption, retraction, cancellation, repurchase

-39,377 vol
17,195
Filed 2018-01-03
Tx date 2018-01-01
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.)
London, John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Share Appreciation Rights Plan (SAR)
38 - Redemption, retraction, cancellation, repurchase

-17,193 vol
39,379
Filed 2017-12-08
Tx date 2017-12-06
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Options
52 - Expiration of options

-53,846 vol
147,446
Filed 2017-12-06
Tx date 2017-12-06
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.)
London, John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
52 - Expiration of options

-53,846 vol
323,891
Filed 2017-06-28
Tx date 2017-06-28
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+18,500 vol
201,292
Filed 2017-03-08
Tx date 2017-03-07
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.)
London, John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+92,408 vol
377,737
Filed 2017-01-04
Tx date 2017-01-01
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.)
London, John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Share Appreciation Rights Plan (SAR)
59 - Exercise for cash
$-462,328.20
-81,828 vol
$5.65 each
56,572
Filed 2017-01-04
Tx date 2017-01-01
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Share Appreciation Rights Plan (SAR)
38 - Redemption, retraction, cancellation, repurchase

-17,193 vol
56,572
Filed 2017-01-04
Tx date 2017-01-01
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Share Appreciation Rights Plan (SAR)
59 - Exercise for cash
$-76,269.30
-64,635 vol
$1.18 each
73,765
Filed 2016-03-24
Tx date 2016-03-23
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.)
London, John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+102,537 vol
285,329
Filed 2016-03-14
Tx date 2016-03-01
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Share Appreciation Rights Plan (SAR)
00 - Opening Balance-Initial SEDI Report
138,400
Filed 2016-03-14
Tx date 2013-10-30
$NRI
Nuvo Research Inc. (formerly Dimethaid Research Inc.)
London, John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Share Appreciation Rights Plan (SAR)
56 - Grant of rights

+169,807 vol
169,807
Filed 2016-03-14
Tx date 2013-10-30
$NRI
Nuvo Research Inc. (formerly Dimethaid Research Inc.)
London, John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Share Appreciation Rights Plan (SAR)
56 - Grant of rights

+169,447 vol
Filed 2016-03-14
Tx date 2016-03-01
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Share Appreciation Rights Plan (SAR)
00 - Opening Balance-Initial SEDI Report
Filed 2016-03-04
Tx date 2016-03-01
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.)
London, John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Deferred Share Unit Plan (DSU)
38 - Redemption, retraction, cancellation, repurchase

-43,882 vol
0
Filed 2016-03-04
Tx date 2016-03-01
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.)
London, John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Deferred Share Unit Plan (DSU)
36 - Conversion or exchange

-57,072 vol
43,882
Filed 2016-03-04
Tx date 2016-03-01
$NRI
Nuvo Pharmaceuticals Inc. (formerly, Nuvo Research Inc.)
London, John
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
36 - Conversion or exchange

+57,072 vol
155,786
Filed 2016-03-04
Tx date 2016-03-01
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Share Appreciation Rights Plan (SAR)
00 - Opening Balance-Initial SEDI Report
138,040
Filed 2016-03-04
Tx date 2016-03-01
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
182,792
Filed 2016-03-04
Tx date 2016-03-01
$CTX
Crescita Therapeutics Inc.
London, John
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
155,786
Filed 2016-02-29
Tx date 2016-02-29
$NRI
Nuvo Research Inc.
London, John
4 - Director of Issuer
Direct Ownership
Options
97 - Other

-7 vol
182,792
Filed 2016-01-06
Tx date 2016-01-01
$NRI
Nuvo Research Inc.
London, John
4 - Director of Issuer
Direct Ownership
Share Appreciation Rights Plan (SAR)
59 - Exercise for cash
$-426,323.88
-81,828 vol
$5.21 each
138,040
Filed 2015-12-11
Tx date 2015-12-09
$NRI
Nuvo Research Inc.
London, John
4 - Director of Issuer
Direct Ownership
Warrants
54 - Exercise of warrants

-10,929 vol
0
Filed 2015-12-11
Tx date 2015-12-09
$NRI
Nuvo Research Inc.
London, John
4 - Director of Issuer
Direct Ownership
Common Shares
54 - Exercise of warrants
$32,787
+10,929 vol
$3.00 each
98,714
Filed 2015-09-24
Tx date 2015-09-21
$NRI
Nuvo Research Inc.
London, John
4 - Director of Issuer
Direct Ownership
Options
52 - Expiration of options
$-399,997
-30,769 vol
$13.00 each
182,799
Filed 2015-06-10
Tx date 2015-06-10
$NRI
Nuvo Research Inc.
London, John
4 - Director of Issuer
Direct Ownership
Common Shares
99 - Correction of information

-1 vol
87,785